Precautions:

• Increased risk of deep vein thrombosis and pulmonary embolism have been reported with EVISTA (see PRECAUTIONS). Women with active or past history of venous thromboembolism should not take EVISTA (see CONTRAINDICATIONS).
• Increased risk of death due to stroke occurred in a trial in postmenopausal women with documented coronary heart disease or at increased risk for major coronary events. Consider risk-benefit balance in women at risk for stroke (see PRECAUTIONS, Clinical Studies).

Conjugated estrogens belong to the class of medications known as estrogen replacement therapy. Estrogen is a female hormone that is produced by the ovaries. Once menopause is reached, the ovaries produce less estrogen and symptoms of menopause can occur. Conjugated estrogen is an estrogen replacement hormone used to manage menopausal symptoms such as abnormal uterine bleeding (spotting), hot flashes, sweating, and chills. This medication may also help treat and prevent osteoporosis caused by estrogen deficiency when combined with diet, calcium, and exercise.

The recommended adult dose of conjugated estrogens ranges from 0.3 mg to 1.25 mg daily, depending on the condition being treated. It is recommended that this medication be taken at the lowest dose possible and for the shortest duration required to treat the condition.

One tablet of Progynova 1mg (FemTab 1mg) to be taken daily. It does not matter at what time of day the woman takes her tablet, but once she has selected a particular time she should keep to it every day. Treatment is continuous, which means that the next pack follows immediately without a break.

For initiation and continuation of treatment of menopausal symptoms, the lowest effective dose for the shortest duration (see also section 4.4) should be used. Treatment to control menopausal symptoms should be initiated with Progynova 1mg (FemTab 1mg). If considered necessary, Progynova 2mg (FemTab 2mg) should be used. Once treatment is established the lowest effective does necessary for relief of symptoms should be used.

It has demonstrated foetal abnormalities or there is evidence of foetal risk based on human experience or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant.